1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Peptide Antibiotics Market & Clinical Pipeline Insight 2023

Global Peptide Antibiotics Market & Clinical Pipeline Insight 2023

  • July 2017
  • 140 pages
  • ID: 5015370
  • Format: PDF
  • By Kuick Research

Summary

Table of Contents

“Global Peptide Antibiotics Market & Clinical Pipeline Insight 2023” report gives comprehensive insight on clinical and non-clinical parameters involved in the development and commercialization of global peptide antibiotics market. As per report findings, peptide antibiotics are expected to emerge as new growth frontier for the various stake holders involved in the research and development of antibiotics. Currently, there are 6 peptide antibiotics commercially available in the market and 24 peptide antibiotics are in clinical pipeline. With the era of “classical antibiotics” coming to an end with problems like heavy resistance to conventional antibiotics, the new era of peptide antibiotics is on its way to revolutionize the antibiotics segment. The peptide antibiotics are at the apex of new generation medications which are sure to storm the markets in the coming years.

Currently, antibiotics are the major source of revenues for the major pharmaceutical players. The demand for antibiotics is rapidly rising with many companies heavily investing in the growth of the antibiotics market. The global antibiotic demand is expected to surpass US$ 40 Billion by 2023 from less than US$ 30 Billion in 2017. However, multiple cases of antibiotic resistance have caused a concern in the healthcare industries which in turn is a major threat to the pharmaceuticals companies as it might cost them a considerable part of their revenues and profit. This situation has led to intensive research and development in the field of peptide antibiotics. The idea of a peptide antibiotic provides a one stop solution to the above issue. The inability of organisms to develop resistance against the newly developed peptide antibiotic, its increased efficacy, high specificity, decreased drug interaction, low toxicity, biological diversity and direct attacking property has made it an efficient product that could have tremendous impact in revolutionizing the new era of antibiotics.

US dominate the global production and commercialization of peptide antibiotics followed by Europe. Companies like Theravance and Vicuron Pharmaceuticals are the major American companies largely dedicated in the development of peptide antibiotics. Their dominance in the global antibiotics market is estimated to remain stable over the next years. However, developing nations like China and India are believed to contribute significantly to the overall growth of the antibiotics market in the near future with their incessant population and demand for antibiotics growing at an alarming rate annually. The success of peptide vaccines would greatly impact the global antibiotics scenario with the conventional antibiotics being replaced. However the rate at which this would happen is still uncertain.

FDA has approved vanomycin and bacitracin as peptide antibiotics, largely used for the treatment of bacterial infection. Recent innovations and advancement in the peptide antibiotics segment has further opened up opportunities in the oncology field with researchers trying to find antibiotics against carcinogenic bacterial infections. Increase in antibiotic resistance, emergence of large scale infections and new opportunities in the oncology segment have led to increased investment in the peptide antibiotics market which seems to be the best alternative healthcare researchers have .These have altogether been the major driving factors in the development of peptide antibiotics.

With the advancement in scientific knowledge and increased research globally, the peptide antibiotics segment is bound to rise. Collaborations between major pharmaceuticals giants fuelled by increased investment and support from various government and foundations have positively impacted the growth in the peptide vaccine market. It is evident that antibiotic resistance would severely impact the antibiotics market, thus the dire need for an alternative. This particular need can successfully be fulfilled by the emergence of peptide antibiotics which would rapidly become an alternative or the most possible solution in situations where the conventional antibiotics fail. Thus it could fairly be concluded that the peptide antibiotics are the new plethora of opportunities with the potential of generating immense revenue in the future.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Pneumonia Global Clinical Trials Review, H1, 2020

Pneumonia Global Clinical Trials Review, H1, 2020

  • $ 2500
  • January 2020

Pneumonia Global Clinical Trials Review, H1, 2020Summaryclinical trial report, “Pneumonia Global Clinical Trials Review, H1, 2020" provides an overview of Pneumonia Disorders Clinical trials scenario.This ...

Community Acquired Pneumonia - Pipeline Review, H1 2020

Community Acquired Pneumonia - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Community Acquired Pneumonia - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Pneumonia - Pipeline Review, H1 2020, provides an overview ...

Otitis Media - Pipeline Review, H1 2020

Otitis Media - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Otitis Media - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Pipeline Review, H1 2020, provides an overview of the Otitis Media (Ear Nose ...


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on